52 results about "Hcv hepatitis" patented technology

The present invention discloses novel compounds which have HCV protease inhibitory activity as well as pharmaceutical compositions comprising such compounds and methods of using them to treat disorders associated with the HCV protease. The novel compounds typically include a 15-20 member macrocycle and have the general structure of structural Formula 1:

wherein Z′, L′, M′, R₁, X and D are defined herein.

The present invention relates to novel hydrazide-containing compounds of Formula I or Formula II, including pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters, or prodrugs thereof:

which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.

Fluorinated oligopeptides, especially those having 4,4-difluoro-2-amino butyric acid at the C terminus, may be effective inhibitors of hepatitis C virus NS3 protease. Examples of hexapeptides of the invention, optimized for binding in the S1 specificity pocket of the enzyme, may display IC50s at the sub-micromolar level. Embodiments of tripeptides of the invention, having a keto-acid group at the C-terminus are, likewise, potent inhibitors of NS3 protease.

The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which can inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.

The present invention is directed to a molecule comprising a polypeptide having substantial homology with a CTL epitope selected from the group consisting of ADLMGYIPLV (Core_131-140; SEQ ID NO:1), LLALLSCLTV (Core_178-187; SEQ ID NO:2), QLRRHIDLLV (SEQ ID NO:55), LLCPAGHAV (NS3_1169-1177; SEQ ID NO:26), KLVALGINAV (NS3_1406-1415; SEQ ID NO:28), SLMAFTAAV (NS4_1789-1797; SEQ ID NO:34), LLFNILGGWV (NS4_1807-1816; SEQ ID NO:35), and ILDSFDPLV (NS5_2252-2260; SEQ ID NO:42). Such molecules are used for the treatment and prevention of acute or chronic HCV hepatitis; suitable pharmaceutical compositions and methods using such compositions are disclosed.

The present invention relates to 4,5-ring annulated indole derivatives of formula (I), compositions comprising at least one 4,5-ring annulated indole derivatives, and methods of using the 4,5-ring annulated indole derivatives for treating or preventing a viral infection or a virus-related disorder in a patient,

wherein ring Z of formula (I), is cyclohexyl, cyclohexenyl, 6-membered heterocycloalkyl, 6-membered heterocycloalkenyl, 6-membered aryl or 6-membered heteroaryl, wherein R¹, R², R³, R⁶, R⁷ and R¹⁰ are as described herein.

There are provided, inter alia, acyclic nucleoside phosphonate compounds having reduced toxicity and enhanced antiviral activity, and pharmaceutically accepted salts and solvates thereof. There are also provided methods of using the disclosed compounds for inhibiting viral RNA-dependent RNA polymerase, inhibiting viral reverse transcriptase, inhibiting replication of virus, including hepatitis C virus or a human retrovirus, and treating a subject infected with a virus, including hepatitis C virus or a human retrovirus.

Compounds of formula I:

wherein X, R², R³, R⁵ and R⁶ are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.

The invention discloses hepatitis c virus NS3/4A protease, a gene and a method for detecting activity of an inhibitor. The nucleotide sequence of the gene is a nucleotide sequence shown as SEQ ID No.1 in a sequence table or the encoded amino acid sequence of the gene is the nucleotide sequence of protein shown as SEQ ID No.2 in the sequence table. According to the method for detecting the activity of the inhibitor, the defects that when a common cell screening model is used for screening medicine, the process is complex, and cost is high are avoided, and the advantages of being clear in medicine acting mechanism, low in cost, high in efficiency, high in sensitiveness and capable of achieving high-throughput screening are achieved.

Genotype 7a has been identified recently, thus not much is known about the biology of this new, major HCV genotype. The present inventors developed hepatitis C virus 7a/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and the complete NS2 were replaced by the corresponding genes of the genotype 7a strain QC69 and characterized them in Huh7.5 cells. Sequence analysis of 7a/JFH1 recombinants recovered after viral passage in Huh7.5 cells following 4 independent transfection experiments revealed adaptive mutations in Core, E2, NS2, NS5A and NS5B. In reverse genetic studies the importance of these mutations for improved growth kinetics was shown. Adapted 7a/JFH1 viruses showed growth kinetics, infectivity and RNA titers comparable to a previously developed 3a/JFH1 reference virus. Conclusion: The developed 7a/JFH1 viruses provide a robust in vitro tool for research in HCV genotype 7, including vaccine studies and functional analyses.

The invention relates to a gene chip for chronic hepatitis C outcome prediction in chronic hepatitis C interferon treatment. The gene chip comprises 12 gene fragments of ISG56, ISG20 and the like. Through the gene chip, in an early stage of chronic hepatitis C interferon treatment on patients or before the chronic hepatitis C interferon treatment on patients, interferon treatment long-term effects can be predicted. Therefore, the gene chip is conducive to optimization and selection of a chronic hepatitis C patient therapeutic schedule, reduces patient pain and treatment costs, and is convenient for detection and clinical application.

The present application provides compounds of formula I wherein X, Y, R², n, R⁵ and R⁶ are defined herein, useful as inhibitors of the hepatitis C virus NS5B polymerase The present application also provides pharmaceutical compositions containing said compounds, methods of using said compounds as pharmaceuticals alone or with other antiviral agent in the treatment of a hepatitis C viral infection in a mammal having or at risk of having the infection.

The invention discloses a hepatitis C virus HVR1 (Hypervariable Region 1) fusion antigen. An amino acid sequence of the fusion antigen is shown as SEQ ID No.1. The invention also discloses application of the fusion antigen in preparation of a hepatitis C virus HVR1 antibody detection kit. The experiment proves that the cross reactivity of the fusion antigen is obviously improved compared with that of a single segment HVR1 antigen, and the detection coincidence rate of hepatitis C virus RNA positive patients is 99 percent. Because the HVR1 is a main neutralizing antigen epitope in the hepatitis C virus, the antigen can be used for achieving an aim of comprehensively detecting HCV infection for hepatitis C virus HVR1 antibody detection and effectively solving the problems such as outcome and prognosis of HCV diseases and prediction of interferon curative effect and has extremely great clinical application prospects.

The invention discloses a method for constructing hepatic c virus specific ribozyme MIGS-hcv/C20, which comprises: selecting a sequence between 21nt and 36nt of hepatitis c virus HCV genomere 5' UTR as a target site to design a guide sequence and obtaining through associating and constructing the guide sequence and escherichia coli ribozyme P covalently. The guide sequence is designed to be effectively combined with the hepatic c virus specific ribozyme successfully through selecting a single-stranded region sequence between the 21nt-36nt of the hepatitis c virus as a candidate target site, the ribozyme which is designed accordingly displays clear targeting cutting activity for a substrate, successful construction of the ribozyme provides experimental materials which are accurate and can be depended for subsequent experiments, and thereby the method lays a foundation for researching new anti-HCV medicine and an antisense gene therapy.

The invention relates to a virus, a composition and the field of preparation or purification thereof, in particular to a chimeric virus of the complete structural protein of a hepatitis C virus and a GB virus B. The chimeric virus is formed by connecting the sequence of a non-coding region on the 5' terminal of the GB virus B, the gene sequence of the complete structural protein of the hepatitis C virus, a nonstructural protein of the GB virus B and the sequence of a non-coding region on a 3' terminal in turn, wherein the gene sequence of the complete structural protein of the hepatitis C virus is the gene sequence of the complete structural protein of 1b genotype hepatitis C virus. The chimeric virus can be used to infect marmoset effectively through the intrahepatic or intravenous injection of the chimeric virus-containing serum of a primary marmoset. The chimeric virus simulates the infection and immune state of the hepatitis C virus in bodies of primates, a platform for testing and evaluating the immunity to the complete structural protein of the hepatitis C virus is provided, and the scientific problems such as limitation on the research on immunity, prevention and control ofhepatitis C virus and vaccine evaluation due to lack of small infected models of primates are solved.

Provided are fused tricyclic compounds effective to inhibit the function of the NS5A protein of formula (I), wherein X, X′, Y, Y′, A, A′, Q¹, Q², R¹-R⁴, X⁴, R^5a, f and W are defined as in the description. Also provided herein are pharmaceutical compositions thereof, and uses in the manufacture of a medicament for treating HCV infection or a HCV disorder thereof.

An application of the high-density lipoprotein (HDL) and its apolipoprotein in preparing the liquid injection or freeze-dried powder injection for treating the envelope virus diseases including influenza, fowl influenza infection, SARS, AIDS, hepatitis B and C, etc is disclosed.